Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV

Journal of Managed Care Pharmacy

Volumn 18, Issue 2, 2012, Pages 129-145

  Johnston, Stephen S ^a   Juday, Timothy ^b   Seekins, Daniel ^b   Espindle, Derek ^a   Chu, Bong Chul ^a  

^a THOMSON REUTERS   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; DATA BASE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREDICTION; PRESCRIPTION; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNITED STATES;

EID: 84860720473     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.2.129     Document Type: Article

References (42)

1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-29. Available at: http://jama.amaassn.org/content/300/5/520.full.pdf+html. Accessed February 3, 2012.
2. Centers for Disease Control and Prevention (CDC). Twenty-Five Years of HIV/AIDS-United States, 1981-2006. MMWR Morb Mortal Wkly Rep. 2006;55(21):585-89. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5521a1.htm. Accessed February 3, 2012.
3. U.S. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 14, 2011;1-167. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 3, 2012.
4. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep. 2006;55(21):589-92. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5521a2.htm. Accessed February 3, 2012.
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30. Available at: http://www.annals.org/content/133/1/21.1.full.pdf+html. Accessed February 3, 2012.
6. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1):158-63. Available at: http://cid.oxfordjournals.org/content/40/1/158.full.pdf. Accessed February 3, 2012.
7. World Health Organization. HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Revised 2006. Available at: www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed February 3, 2012.
8. Tapper ML, Flexner C, Eron JJ, Molina JM. Simplifying antiretroviral therapy. AIDS Read. 2004;14(7):355-60,367-71.
9. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;18(11):1503-11. Available at: http://journals.lww.com/aidsonline/fulltext/2004/07230/evolution_of_resistance_to_drugs_in_hiv_1_infected.4.aspx. Accessed February 3, 2012.
10. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr. 2005;40(1):34-40. Available at: http://www.medscape.com/viewarticle/512015. Accessed February 3, 2012.
11. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79-S87. Available at: http://journals.lww.com/jaids/Fulltext/2006/12011/Practical_and_Conceptual_Challenges_in_Measuring.11.aspx. Accessed February 3, 2012.
12. Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187-91.
13. Kitahata MM, Reed SD, Dillingham PW, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15(12):803-10.
14. Institute of Medicine. Committee on HIV Screening and Access to Care. HIV Screening and Access to Care: Exploring the Impact of Policies on Access to and Provision of HIV Care. Washington, DC: The National Academies Press; 2011. Available at: http://www.iom.edu/Reports/2011/HIV-Screeningand-Access-to-Care-Exploring-the-Impact-of-Policies-on-Access-to-and-Provision-of-HIV-Care.aspx. Accessed February 3, 2012.
15. U.S. Department of Health and Human Services. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. February 4, 2002;1-96. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL04232001006.pdf. Accessed February 3, 2012.
16. U.S. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2007;1-144. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000721.pdf. Accessed February 3, 2012.
17. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-64.
18. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12. Available at: http://www.ispor.org/workpaper/research_practices/Peterson_Scientific_Report.pdf. Accessed February 3, 2012.
19. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114(7):573-80.
20. Herrmann S, McKinnon E, John M, et al. Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care. Intern Med J. 2008;38(1):8-15. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1445-5994.2007.01477.x/pdf. Accessed February 3, 2012.
21. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav. 2005;9(3):355-62.
22. Sherr L, Lampe F, Norwood S, et al. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care. 2008;20(4):442-48.
23. Lovejoy TI, Suhr JA. The relationship between neuropsychological functioning and HAART adherence in HIV-positive adults: a systematic review. J Behav Med. 2009;32(5):389-405. Available at: http://www.springerlink.com/content/2l21877217jpj704/fulltext.pdf. Accessed February 3, 2012.
24. U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Index detailed report tables annual average 2008. Available at: http://www.bls.gov/cpi. Accessed February 3, 2012.
25. Hardin JW, Hilbe JM. Generalized Estimation Equations. Boca Raton, FL: Chapman & Hall/CRC; 2003.
26. Collins RL, Kanouse DE, Gifford AL, et al. Changes in health-promoting behavior following diagnosis with HIV: prevalence and correlates in a national probability sample. Health Psychol. 2001;20(5):351-60.
27. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74(368):829-36.
28. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm. 2008;14(3):291-301. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_April08_291-301.pdf.
29. Collins RL, Kanouse DE, Gifford AL, et al. Changes in health-promoting behavior following diagnosis with HIV: prevalence and correlates in a national probability sample. Health Psychol. 2001;20(5):351-60.
30. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-16. Available at: http://napwa.org.au/files/Stone_J%20Acquir%20Immune%20Defic%20Syndr_2004.pdf. Accessed February 3, 2012.
31. Das-Douglas M, Riley ED, Ragland K, et al. Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav. 2009;13(1):1-9.
32. Henry J. Kaiser Family Foundation. Fact sheet. Medicare: low-income assistance under the Medicare drug benefit. May 2006. Available at: http://www.allhealth.org/briefingmaterials/Lowincomemedicareassistance-305.pdf. Accessed February 3, 2012.
33. Cohn SE, Jiang H, McCutchan JA, et al. Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care. 2011;23(6):775-85.
34. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411-17. Available at: http://journals.lww.com/jaids/Fulltext/2006/12010/Hazardous_Alcohol_Use__A_Risk_Factor_for.5.aspx. Accessed February 3, 2012.
35. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8229.
36. Zhang D, Carlson AM, Gleason PP, et al. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. J Manag Care Pharm. 2007;13(8):664-76. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7725.
37. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-34. Available at: http://www.ajmc.com/media/pdf/AJMC_2010janMaciej_WEB_e20to34.pdf. Accessed February 3, 2012.
38. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost-sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. Available at: http://jama.ama-assn.org/content/298/1/61.full.pdf+html. Accessed February 3, 2012.
39. Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339(26):1897-904. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJM199812243392606. Accessed February 3, 2012.
40. Chernew ME, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008;23(8):1131-36. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2517964/pdf/11606_2008_Article_614.pdf. Accessed February 3, 2012.
41. Fairman KA. The future of prescription drug cost-sharing: real progress or dropped opportunity? J Manag Care Pharm. 2008;14(1):70-82. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_JanFeb%2008_070-082.pdf.
42. Fairman KA, Curtiss FR. Still looking for health outcomes in all the wrong places? Misinterpreted observational evidence, medication adherence promotion, and value-based insurance design. J Manag Care Pharm. 2009;15(6):501-07. Available at: http://www.amcp.org/data/jmcp/501-507.pdf.